Acrivon Therapeutics, Inc. Common Stock (ACRV) Financials

ACRV Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 107.8 million 12.3 million
Dec. 31, 2025 129.7 million 17.2 million
Sept. 30, 2025 145.3 million 16.7 million
June 30, 2025 158.6 million 15.5 million

ACRV Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -20.6 million 2.2 million
Dec. 31, 2025 -15.5 million 3.1 million
Sept. 30, 2025 -13.2 million 3.9 million
June 30, 2025 -17.1 million 3.9 million

ACRV Net Income

No data available :(

ACRV Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 97.7 million 1.3 million 2.4 million
Dec. 31, 2025 118.6 million - 2.7 million
Sept. 30, 2025 129.3 million 1.8 million 3.0 million
June 30, 2025 137.4 million - 2.1 million

ACRV Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 38.7 million
Dec. 31, 2025 38.5 million
Sept. 30, 2025 38.6 million
June 30, 2025 38.5 million

ACRV Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 14000 14.8 million 4.7 million -
Dec. 31, 2025 219000 15.0 million 5.4 million -
Sept. 30, 2025 899000 13.6 million 6.0 million -
June 30, 2025 493000 16.2 million 6.5 million -

ACRV Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 383000
Dec. 31, 2025 - -911000
Sept. 30, 2025 - 300000
June 30, 2025 - 300000

ACRV

Price: $1.57

52 week price:
1.15
3.56

Earnings Per Share: -2.00 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 45.1 million

Links: